DNA-PK inhibitors, including NU7026 58, NU7441 59, IC87361 60, and M3814 61, have been developed to inhibit the repair pathway of the double-strand break and increase the sensitivity of cancer cells to radiation therapy and chemotherapy. Here, PRKDC is linked to cancer.